Proactive Investors - Run By Investors For Investors

Scancell hails 'ringing endorsement' of its cancer technology

A paper in Cancer Research, a leading journal for doctors and surgeons specialising in this area of medicine, outlined the company’s innovative approach to generating vaccines that fight the disease.
Scancell hails 'ringing endorsement' of its cancer technology
Scancell has a unique approach to treating cancer.


Scancell Holdings (LON:SCLP) hailed as a ‘ringing endorsement’ of its technology the publication of a paper describing the science behind its Moditope platform and the experimental results that support it.

The piece in the online edition of Cancer Research, a leading journal for doctors and surgeons specialising in this area of medicine, outlined the company’s innovative approach to generating vaccines that fight the disease.

The immunotherapy has generated a number of drug candidates, led by Modi-1, which is in later stages of pre-clinical development.

First-in-man studies will assess its potential to combat triple negative breast cancer, a strain that is resistant to current mainstream treatments.

Scancell’s joint chief executive, Professor Lindy Durrant, said: "The publication of this paper on the science behind Moditope in such a prestigious and widely read cancer journal is not only a great achievement for the research team at Scancell, it provides a ringing endorsement from the scientific community for this completely innovative approach to the treatment of cancer. 

“This important paper lays out the foundation, rationale and experimental basis for the Moditope platform and its potential to generate effective cancer vaccines."

Panmure Gordon added: “We continue to consider the field of immuno-oncology as compelling and believe publications such as this potentially broaden the recognition of the company’s technical expertise.”

In particular, the broker noted that the paper should further widen the recognition of Scancell’s Moditope platform which is supporting the Modi-1 lead product through preclinical studies.

Moditope is one of two platform technologies being developed by the company.

The other, ImmunoBody, has generated a number of potential treatments in the emerging area of immune-oncology, where the immune system is used to fight cancer.

Chief among them is SCIB1, which has delivered highly encouraging early results when used in difficult-to-treat patients with melanoma.

Shares in Scancell were broadly flat at 19.75p on Tuesday.

View full SCLP profile View Profile

Scancell Holdings Plc Timeline

February 08 2018

Related Articles

m&a icon of bug fish swallowing big fish
December 04 2017
It is paying an initial US$13mln for Vamousse, which it is acquiring from TyraTech, the AIM-listed developer of the range. This will be followed by a deferred pay-out of as much as US$4.5mln based on sales targets
Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Richard Lipscombe talked revenue generation and growth path with investors.
picture of human skeleton
January 16 2018
Tissue Regenix is funding the acquisition with a placing at 10p to raise £40mln

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use